The beneficial effects of hepatic FASN deficiency on nonalcoholic fatty liver disease and glucose metabolism are associated with the inhibition of de novo lipogenesis and the attenuation of gluconeogenesis and fatty acid oxidation, respectively (69, 70). Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.